Dataset Information

Multicenter Phese II Study of SOX plus Bevacizumab Therapy with Oxaliplatin Stop-and-Go Strategy and Oral S-1 plus Bevacizumab Maintenance Therapy in Advanced Colorectal CancerC

ABSTRACT: Interventions: (1)Initial therapy : SOX+bevacizumab therapy Bev : 7.5 mg/kg (90 min) L-OHP : 130 mg/m2 (120 min) S-1 : 80 - 120 mg/day (Day1-15) (2)Maintenance therapy : S-1+bevacizumab therapy Bev : 7.5 mg/kg (90 min) S-1 : 80 - 120 mg/day (Day1-15) (3)Reintroduced therapy : SOX+bevacizumab therapy Primary outcome(s): DDC ; Duration of disease control) Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Metastatic Or Recurrent Colorectal Cancer

PROVIDER: 2627046 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:Interventions: Step1: Confirmation of dosage of each drug (Oxaliplatin and Irinotecan) i)Induction treatment The following drugs will be administered in 3week/cycle for 6cycles (maximum 8cycle, if investigator required). With regard to determination of oxaliplatin (OX) and Irinotecan (IRI) dosage, initial 3patients (pts) will be enrolled of level0. After finishing initial enrollment, Steering committee (SC) will evaluate safety of 3pts at the time of starting of cycle2 and will decide whether the proceeding same level (add 3 pts) or other level (level+1 or level-0.5). Final decision of Recommended Dose (RD) of OX and IRI will be required 6pts of safety evaluation in same level and will be endorsed by SC and Independent Data monitoring committee (IDMC). 1) Each drug dosage of CAPOXIRI+Bevacizumab Bevacizumab (BEV: 7.5 mg/kg, i.v., 90, 60, 30 min, Day 1) Irinotecan (IRI: 130 mg/m2, i.v., 90 min, Day 1) Oxaliplatin (OX: 200 mg/m2, i.v., 120 min, Day 1) Capecitabine (CAP: 800 mg/m2 p.o., twice daily, 14 days consecutively) 2) OX and IRI dose level Level +1: IRI: 200 mg/m2, OX:130mg/m2 Level 0: IRI: 200 mg/m2, OX:100mg/m2 Level -0.5: IRI: 180 mg/m2, OX:100mg/m2 Level -1: IRI: 150 mg/m2, OX:100mg/m2 ii)Maintenance treatment After finishing the induction treatment, investigator will select 1) 5-FU/LV+BEV (2weeks cycle) or 2) CAP+BEV treatment (3weeks/cycle). 1)5-FU/LV+BEV treatment The following drugs will be administered in 2week/cycle until meeting discontinuation criteria. - Each drug dosage of 5-FU/LV+BEV - Bevacizumab (BEV: 5.0 mg/kg, i.v., 90, 60, 30 min, Day 1) Leucovorin (LV: 200 mg/m2, i.v., 120 min, Day 1) 5-FU (3200 mg/m2, c.i.v., 48 hours, Day 1-3) 2)CAP+BEV treatment The following drugs will be administered in 2week/cycle until meeting discontinuation criteria. - Each Primary outcome(s): Progression-free survival (PFS) Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose

Dataset Information

Multicenter Phese II Study of SOX plus Bevacizumab Therapy with Oxaliplatin Stop-and-Go Strategy and Oral S-1 plus Bevacizumab Maintenance Therapy in Advanced Colorectal CancerC

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets